Reata Pharmaceuticals Inc
RETADelisted Sep 26, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001358762
Reata Pharmaceuticals Inc was delisted on Sep 26, 2023; its insiders filed their last Form 4 on Sep 28, 2023; 214 institutions reported holding it in 13F filings for Q2 2023, worth $3.21B in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 214
- Q2 2023, +10 vs. previous quarter
- 13F value
- $3.21B
- Reported value at the end of Q2 2023
- Superinvestors holding
- 0
- At the end of Q2 2023
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2022
- $2.22M
- −80.7% year over year
- Net income, FY2022
- -$311.9M
- No comparable prior period
- Free cash flow, FY2022
- -$207.5M
- No comparable prior period
- Revenue, Q2 FY2023
- $22.7M
- +2,885.0% year over year
Superinvestors holding RETA, Q2 2023
Go to the superinvestors tabNo superinvestor reported holding RETA at the end of Q2 2023.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Reata Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2023 (view filing) | Sep 14 | 4 days | Loewen AndreaSVP, Global Regulatory Affairs | SSaleClass A common stock | −3.17K | $172.03 | −$546.2K | −10.1%28.4K after | |
| Sep 7, 2023 (view filing) | Sep 5 | 2 days | Anand BhaskarSVP, Chief Accounting Officer | SSaleClass A common stock | −406 | $169.20 | −$68.7K | −1.7%24.1K after | |
| Aug 17, 2023 (view filing) | Aug 15-16 | 2 days | Wortley Michael DChief Legal Officer | SSaleClass A common stock | −1.21K | $168.95 | −$203.6K | −2.4%49.7K after | 2 lots |
| Aug 17, 2023 (view filing) | Aug 16 | 1 day | Soni Manmeet SinghCOO, CFO and President | SSaleClass A common stock | −1.75K | $168.41 | −$295.6K | −2.7%62.6K after | |
| Aug 17, 2023 (view filing) | Aug 15-16 | 2 days | Meyer Colin JohnChief Innovation Officer | SSaleClass A common stock | −2.74K | $169.00 | −$463.1K | −3.2%81.6K after | 2 lots |
| Aug 17, 2023 (view filing) | Aug 15-16 | 2 days | Bir Dawn CarterChief Commercial Officer | SSaleClass A common stock | −1.21K | $168.81 | −$203.4K | −3.4%33.8K after | 2 lots |
| Aug 17, 2023 (view filing) | Aug 15-16 | 2 days | Anand BhaskarSVP, Chief Accounting Officer | SSaleClass A common stock | −403 | $168.73 | −$68.0K | −1.6%24.5K after | 2 lots |
| Aug 1, 2023 (view filing) | Jul 28 | 4 days | Soni Manmeet SinghCOO, CFO and President | SSaleClass A common stock | −75.0K | $164.62 | −$12.3M | −53.8%64.4K after | 10b5-1 |
| Aug 1, 2023 (view filing) | Jul 28 | 4 days | Ruff ShamimDirector | SSaleClass A common stock | −8.23K | $164.53 | −$1.35M | −52.8%7.36K after | 10b5-1 |
| Aug 1, 2023 (view filing) | Jul 28 | 4 days | McClellan William D. Jr.Director | SSaleClass A common stock | −5.00K | $164.49 | −$822.5K | −45.4%6.02K after | 10b5-1 |
Top 10 13F holders, Q2 2023
See all 214 holdersThe largest institutional positions in Reata Pharmaceuticals Inc at the end of Q2 2023; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| CPMG Inc | 2,896,901 | $295.4M | 59.26% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,821,537 | $287.7M | 0.01% | +70,596+2.6% | Added |
| BlackRock Inc. | 2,538,770 | $258.9M | 0.01% | +329,021+14.9% | Added |
| Adage Capital Partners GP, L.L.C. | 1,766,070 | $180.1M | 0.39% | +1,296,452+276.1% | Added |
| Deutsche Bank AG | 1,486,467 | $151.6M | 0.08% | −8,410−0.6% | Reduced |
| Wellington Management Group LLP | 1,472,043 | $150.1M | 0.03% | +50,881+3.6% | Added |
| First Light Asset Management, LLC | 1,432,208 | $146.0M | 11.45% | −154,720−9.7% | Reduced |
| Boxer Capital, LLC | 1,430,004 | $145.8M | 6.76% | +200,000+16.3% | Added |
| Janus Henderson Group PLC | 1,051,077 | $107.2M | 0.07% | +827,758+370.7% | Added |
| State Street Corp | 713,150 | $72.7M | 0.00% | +80,205+12.7% | Added |
Politician trades
All politician trades in RETA1 member of Congress reported 2 trades in Reata Pharmaceuticals Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Feb 17, 2021 |  Chris Jacobs House · NY | Sell | $1K-$15K |
| Feb 10, 2021 | Chris Jacobs House · NY | Buy | $1K-$15K |
House · NY · Feb 17, 2021
Sell$1K-$15K
House · NY · Feb 10, 2021
Buy$1K-$15K